Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test

Diagnostic Microbiology and Infectious Disease

Volumn 77, Issue 1, 2013, Pages 25-30

  Pyne, Michael T ^a   Hillyard, David R ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Genotype; HCV; Real time PCR; Viral load

Indexed keywords

VIRUS RNA;

ANALYTICAL EQUIPMENT; ARTICLE; AUTOANALYZER; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LINEAR SYSTEM; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; ROBOTICS; SENSITIVITY ANALYSIS; VIRUS INHIBITION; VIRUS LOAD;

EID: 84881548860     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.05.012     Document Type: Article

References (32)

1. Akhavan S., Ronsin C., Laperche S., Thibault V. Genotype 4 hepatitis C virus: beware of false-negative RNA detection. Hepatology 2011, 53:1066-1067.
2. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
3. Bossler A., Gunsolly C., Pyne M.T., Rendo A., Rachel J., Mills R., et al. Performance of the COBAS Ampliprep/COBAS TaqMan automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J Clin Virol 2011, 50:100-103.
4. Caliendo A.M., Valsamakis A., Zhou Y., Yen-Lieberman B., Andersen J., Young S., et al. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol 2006, 44:1726-1732.
5. Chevaliez S., Bouvier-Alias M., Castéra L., Pawlotsky J.M. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 2009, 49:1397-1398.
6. Colucci G., Ferguson J., Harkleroad C., Lee S., Romo D., Soviero S., et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure System: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007, 45:3595-3600.
7. Davis G.L., Alter J.M., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
8. Elkady A., Tanaka Y., Kurbanov F., Sugauchi F., Sugiyama M., Khan A., et al. Performance of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV Genotypes 1-4. J Med Virol 2010, 82:1878-1888.
9. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
11. Germer J.J., Bommersbach C.E., Schmidt D.M., Bendel J.L., Yao J.D.C. Quantification of genotype 4 hepatitis C virus RNA by the COBAS AmpliPrep/COBAS TaqMan hepatitis C virus test. Hepatology 2009, 50:1679-1680.
12. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
13. Halfon P., Martinot-Peignoux M., Khiri H., Marcellin P. Quantification of genotype 4 serum samples: impact of hepatitis C virus genetic variability. Hepatology 2010, 52:401.
14. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
15. Hofmann W.P., Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011, 8:257-264.
16. Jacobson I.M., Marcellin P., Zeuzem S., Sulkowski M.S., Esteban R., Poordad F., et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012, 56:567-575.
17. Konnick E.Q., Williams S.M., Ashwood E.R., Hillyard D.R. Evaluation of the COBAS hepatitis C virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. J Clin Microbiol 2005, 43:2133-2140.
18. Kwo P.Y., Zhao R. Boceprevir: a user's guide. Clin Liver Dis 2011, 15:537-553.
19. Liapakis A., Jacobson I. Telaprevir user's guide. Clin Liver Dis 2011, 15:555-571.
20. Merck & Co., Inc Victrelis prescribing information - Revised 12/2012. 2012 [cited 2013 Feb]; Available from: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.
21. Pittaluga F., Allice T., Abate M.L., Ciancio A., Cerutti F., Varetto S., et al. Clinical evaluation of the COBAS AmpliPrep/COBAS TaqMan for HCV RNA quantification in comparison with the branched-DNA assay. J Med Virol 2008, 80:254-260.
22. Pyne M.T., Konnick E.Q., Phansalkar A., Hillyard D.R. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol 2009, 47:2872-2878.
23. Roche Molecular Systems AmpliPrep/COBAS TaqMan HCV Test: Product Insert, Revision 3 2010, Roche Molecular Systems, Branchburg, NJ.
24. Sarrazin C., Gärtner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotype 1 to 5. J Clin Microbiol 2006, 44:729-737.
25. Sarrazin C., Dragan A., Gärtner B.C., Forman M.S., Traver S., Zeuzem S., et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS AmpliPrep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 2008, 43:162-168.
26. Sizmann D., Boeck C., Boelter J., Fischer D., Miethke M., Nicolaus S., et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J ClinVirol 2007, 38:326-333.
27. The Medical Letter, Inc. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. Med Lett Drugs Ther 2011, 53:57-59.
28. Trimoulet P., Merchadou L., Winnock M., Loko M.A., Fleury H., Salmon D., et al. Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?. J Virol Methods 2012, 181:131-133.
29. Vermehren J., Kau A., Gärtner B.C., Göbel R., Zeuzem S., Sarrazin C. Differences between two real-time PCR based assays (RealTime HCV, COBAS Ampliprep/COBAS TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for HCV RNA detection and quantification. J Clin Microbiol 2008, 46:3880-3891.
30. Vermehren J., Colucci G., Gohl P., Amdi N., Abdelaziz A.I., Karey U., et al. Development of a second version of the Cobas AmpliPRep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol 2011, 49:3309-3315.
31. Vertex Pharmaceuticals, Inc Incivek prescribing information - Revised 12/2012. 2012 [cited 2013 Feb]; Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf.
32. Vierling J.M. Hepatitis C, virus viral assays in the direct-acting antiviral era. Clin Liver Dis 2013, 17:27-45.